Trial register facet
Trial records in obesity and overweight in adults
208 records bearing on obesity and overweight in adults.
Showing 0 records on this page
Records
208 documents · page 1 of 9
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURMOUNT-5 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 751 | 2025 | High |
| SURMOUNT-KOA | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Low |
| ATTAIN-1 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Moderate |
| ATTAIN-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| REDEFINE-1 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 3,417 | 2025 | Moderate |
| REDEFINE-2 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,206 | 2025 | Moderate |
| GLORY-1 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 610 | 2025 | Moderate |
| ECNO-PH3-CN-OBESITY | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 664 | 2025 | Low |
| SURMOUNT-KOA-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-1-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-1-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-2-OLEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| GLORY-1-QOLprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-OBESITY-REGIONAL-JPprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURMOUNT-KOA-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| REDEFINE-2-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-OBESITY-BODY-COMPprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURMOUNT-5-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| REDEFINE-1-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-BIOMARKERprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
page 1 of 9